drugset
drugset / Trial / NCT05389696

Clinical Trial to Evaluate Pharmacokinetic Characteristics of MIT-001 After SC Administration in Healthy Subjects

NCT05389696 ↗

Phase 1 Completed 40 enrolled MitoImmune Therapeutics
RandomizedParallel-groupTriple-blindOther

Summary

1. Part 1 Randimization, Double blinded, Placebo controlled, Dose escalation(10mg, 20mg, 40mg) of MIT-001 SC or IV single administration to evaluate safety, tolerability and PK in healthy adult. 2. Part2 Randimization, Double blinded, Placebo controlled, MIT-001 SC multiple administration for 7days (20mg \& 40mg) to evaluate safety, tolerability and PK in healthy adult.

Timeline

Start
2022-05-13
Primary completion
2023-02-13
Completion
2023-04-28

Drugs

EvaluationDrugModalityDoseRoute
Subject MIT-001 Unknown 10 mg Subcutaneous
Subject MIT-001 Unknown 20 mg Subcutaneous
Subject MIT-001 Unknown 40 mg Subcutaneous

Indications

No indication recorded.